Tetraphase Pharmaceuticals Announces Positive Data from Post-Hoc Analysis of Phase 3 Trials

Tetraphase Pharmaceuticals (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, announced data from two post-hoc analyses of pooled data from two Phase 3 IGNITE (Investigating Gram-Negative Infections Treated with Eravacycline) studies of XERAVA in patients with complicated intra-abdominal infections (cIAI).

As quoted in the press release:

These data were presented at the 2018 American College of Clinical Pharmacy (ACCP) Global Conference on Clinical Pharmacy, held October 20-23 in Seattle, WA.

“Treatment failure risk can increase in certain subgroups with cIAI, including patients who are obese, and those with altered renal function,” said Larry Tsai, M.D., Chief Medical Officer of Tetraphase. “Obesity may put patients at higher risk due to altered pharmacokinetics and comorbidities, while renal function can be highly dynamic in patients with serious infections, which can result in significant over- or under-dosing of antibiotics.”

Dr. Tsai added, “We believe the data presented at the 2018 ACCP Global Conference confirm the efficacy of XERAVA in both obese and renally impaired high-risk patient populations. In fact, one of the many benefits of XERAVA is that physicians do not have to dose adjust the therapy for renally impaired patients, which when combined with this post-hoc sub-analysis, highlight how XERAVA is an ideal option for those with altered renal function. Overall, these pooled data from two Phase 3 IGNITE studies further reinforce the use of XERAVA as an empiric treatment of choice for appropriate patients.”

Click here to read the full press release.